Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 457 | 0.660 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2020 | 6 | 0.640 |
Why?
|
| Ampulla of Vater | 1 | 2020 | 12 | 0.640 |
Why?
|
| Enoxaparin | 1 | 2020 | 17 | 0.630 |
Why?
|
| Leukemia, Large Granular Lymphocytic | 1 | 2018 | 1 | 0.560 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 147 | 0.560 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2018 | 28 | 0.550 |
Why?
|
| Aortic Valve Stenosis | 1 | 2020 | 190 | 0.510 |
Why?
|
| Immunotherapy | 1 | 2019 | 265 | 0.490 |
Why?
|
| Pancreatic Neoplasms | 3 | 2020 | 349 | 0.470 |
Why?
|
| Anticoagulants | 1 | 2020 | 511 | 0.460 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 358 | 0.400 |
Why?
|
| Neoplasms | 2 | 2021 | 1392 | 0.360 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2011 | 19 | 0.350 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2011 | 14 | 0.350 |
Why?
|
| Myeloproliferative Disorders | 1 | 2011 | 17 | 0.350 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2011 | 11 | 0.350 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 495 | 0.310 |
Why?
|
| Repressor Proteins | 1 | 2011 | 348 | 0.300 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 309 | 0.270 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 210 | 0.230 |
Why?
|
| Survival Rate | 4 | 2020 | 859 | 0.210 |
Why?
|
| Middle Aged | 10 | 2021 | 17898 | 0.200 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2016 | 174 | 0.190 |
Why?
|
| Mutation | 3 | 2021 | 2629 | 0.190 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1211 | 0.180 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 22 | 0.170 |
Why?
|
| Anus Neoplasms | 1 | 2021 | 25 | 0.170 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 58 | 0.170 |
Why?
|
| Humans | 14 | 2021 | 64238 | 0.160 |
Why?
|
| Albumins | 1 | 2020 | 37 | 0.160 |
Why?
|
| Deoxycytidine | 1 | 2020 | 43 | 0.160 |
Why?
|
| Paclitaxel | 1 | 2020 | 103 | 0.150 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 132 | 0.150 |
Why?
|
| Appendiceal Neoplasms | 1 | 2018 | 9 | 0.150 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2018 | 32 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 259 | 0.140 |
Why?
|
| Geriatrics | 1 | 2019 | 43 | 0.140 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 529 | 0.140 |
Why?
|
| Vaccination | 1 | 2021 | 371 | 0.140 |
Why?
|
| Aged | 6 | 2020 | 14648 | 0.140 |
Why?
|
| Antineoplastic Agents | 3 | 2012 | 666 | 0.140 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 695 | 0.140 |
Why?
|
| Coronary Artery Bypass | 1 | 2020 | 297 | 0.140 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2020 | 176 | 0.130 |
Why?
|
| Dihydropyrimidine Dehydrogenase Deficiency | 1 | 2017 | 1 | 0.130 |
Why?
|
| Capecitabine | 1 | 2017 | 15 | 0.130 |
Why?
|
| Fluorouracil | 1 | 2017 | 69 | 0.130 |
Why?
|
| Male | 8 | 2021 | 30294 | 0.120 |
Why?
|
| Female | 8 | 2021 | 33350 | 0.110 |
Why?
|
| Quality of Life | 2 | 2020 | 1257 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 984 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 355 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2020 | 1294 | 0.100 |
Why?
|
| Carboplatin | 1 | 2012 | 43 | 0.090 |
Why?
|
| Radioimmunotherapy | 1 | 2012 | 8 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2012 | 28 | 0.090 |
Why?
|
| Pyrazines | 1 | 2012 | 35 | 0.090 |
Why?
|
| Imatinib Mesylate | 1 | 2011 | 34 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2012 | 77 | 0.090 |
Why?
|
| Aromatase Inhibitors | 1 | 2011 | 25 | 0.090 |
Why?
|
| Benzamides | 1 | 2011 | 66 | 0.090 |
Why?
|
| Piperazines | 1 | 2011 | 87 | 0.080 |
Why?
|
| Triazoles | 1 | 2011 | 62 | 0.080 |
Why?
|
| Nitriles | 1 | 2011 | 79 | 0.080 |
Why?
|
| Receptors, Progesterone | 1 | 2011 | 110 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2011 | 146 | 0.080 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 130 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 247 | 0.080 |
Why?
|
| Prognosis | 3 | 2021 | 1769 | 0.080 |
Why?
|
| DNA Mutational Analysis | 2 | 2021 | 197 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 313 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 869 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2021 | 101 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2021 | 197 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 192 | 0.040 |
Why?
|
| France | 1 | 2020 | 14 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2020 | 12 | 0.040 |
Why?
|
| Spain | 1 | 2020 | 33 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 20 | 0.040 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2020 | 10 | 0.040 |
Why?
|
| Italy | 1 | 2020 | 68 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 151 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 176 | 0.040 |
Why?
|
| Safety | 1 | 2020 | 145 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 2478 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 10 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 91 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 142 | 0.040 |
Why?
|
| beta Catenin | 1 | 2018 | 99 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 63 | 0.040 |
Why?
|
| Adult | 3 | 2021 | 17116 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2016 | 11 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2016 | 19 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 42 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 1176 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2016 | 120 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2020 | 5691 | 0.030 |
Why?
|
| Rectal Neoplasms | 1 | 2017 | 128 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 512 | 0.030 |
Why?
|
| United States | 2 | 2020 | 7923 | 0.020 |
Why?
|
| Bortezomib | 1 | 2012 | 56 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2012 | 58 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 76 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 467 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 215 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 5520 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2012 | 3315 | 0.010 |
Why?
|